BTG selects inVentiv Commercial to provide sales and training for CroFab, DigiFab products

inVentiv Commercial, a division of inVentiv Health and the industry leader in outsourced sales teams to the pharmaceutical industry, announced today that it has been selected by international specialty pharmaceuticals company BTG International Inc to provide a sales team, as well as training and fulfillment services, for the company's CroFab® and DigiFab® products. CroFab® is an antidote used to treat envenomation from Crotalid snakes, and DigiFab® is a treatment for life-threatening digoxin (digitalis) toxicity or overdose.

"inVentiv is extremely pleased to be collaborating with BTG," said Eric Sirota, President of inVentiv Commercial. "We look forward to putting our experienced sales teams and expert training and fulfillment services to work for CroFab® and DigiFab®, vitally important products for toxicity and venom treatment."

"We look forward to working with inVentiv Commercial," said Dan Schneider, Vice President of Sales & Marketing, BTG. "Their experience in recruiting and deploying high-quality sales teams will be an asset to BTG as we focus on promoting these important products."


inVentiv Health, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Big pharma went all in to kill drug pricing negotiations